Antiphospholipid syndrome: A comprehensive review of a complex and multisystemic disease

Clinical and Experimental Rheumatology

Volumn 27, Issue 4, 2009, Pages 668-677

  Palomo, I ^a   Segovia, F ^a   Ortega, C ^a   Pierangeli, Silvia ^b  

^a UNIVERSIDAD DE TALCA   (Chile)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Lupus anticoagulant; Pregnancy loss; Thrombosis

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTIPLASMIN; ANTITHROMBIN III; APOLIPOPROTEIN E2; BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR; CARDIOLIPIN ANTIBODY; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRIN; HEPARIN; INTERCELLULAR ADHESION MOLECULE 1; LIPOCORTIN 2; LUPUS ANTICOAGULANT; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOLIPID ANTIBODY; PLASMIN; PLASMINOGEN; PROTHROMBIN; THROMBIN; THROMBOXANE A2; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VON WILLEBRAND FACTOR;

ANTIPHOSPHOLIPID SYNDROME; BINDING AFFINITY; CELL SURFACE; CLINICAL FEATURE; COMPLEMENT SYSTEM; DISEASE CLASSIFICATION; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; LABORATORY TEST; MONOCYTE; MONOTHERAPY; PATHOPHYSIOLOGY; PREGNANCY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TARGET CELL; THROMBOCYTE; THROMBOSIS;

ABORTION, HABITUAL; ADULT; ANIMALS; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HYDROXYCHLOROQUINE; PLASMA EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOSIS;

EID: 70350149398     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. EGEBERG O: Thrombophilia caused by inheritable deficiency of blood antithrombin. Scand J Clin Lab Invest 1965; 17: 92.
2. PEREIRA J, CONTE G, PALOMO I: Trombofilias. Hematología: Fisiopatología y Diagnóstico. PALOMO I, PEREIRA J, PALMA J (Eds.). Capítulo 24: Universidad de Talca; 2005.
3. HARRIS EN, PIERANGELI SS: Primary, Secondary, Catastrophic antiphospholipid syndrome: is there a difference? Thromb Res 2004; 114: 357-361
4. ASHERSON RA, PIETTE J-C, CERVERA R: "Primary", "Secondary", "Seronegative", "Catastrophic" and other subsets of the Antiphospholipid Syndrome. In: ASHERSON RA, CERVERA R, PIETTE J-C, SHOENFELD Y (Eds.) The Antiphospholipid Syndrome II Autoimmune thrombosis. Elsevier Pub 2002 The Netherlands. p.285-296
5. LEVY R, GHARAVI A, SAMMARITANO L et al.: Characteristics of IgG antiphospholipid antibodies in patients with systemic lupus erythematosus and syphilis. J Rheumatol 1990; 17: 1036-1041 (Pubitemid 20278020)
6. YOON K, WONG A, SHAKESPEARE T et al.: High prevalence of antiphospholipid antibodies in Asian cancer patients with thrombosis. Lupus 2003; 12: 112-116
7. MERRILL J, SHEN C, GUGNANI M et al.: High prevalence of antiphospholipid antibodies in patients taking procainamide. J Rheumatol 1997; 24: 1083-1088
8. AMITAL H, GOVONI M, MAYA R et al.: Role of infectious agents in systemic rheumatic diseases. Clin Exp Rheumatol 2008; 26: S27-32.
9. Petri M: Epidemiology of the antiphospholipid antibody syndrome. J Autoimmun 2000; 15: 145-151
10. DOMENICO SEBASTIANI G, MINISOLA G, GALEAZZI M: HLA class II alleles and genetic predisposition to the antiphospholipid syndrome. Autoimmun Rev 2003; 2: 387-394
11. PETRI M: The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort Thromb Res 2004; 114: 593-595 (Pubitemid 39422596)
12. PALOMO I, PEREIRA J, ALARCON M et al.: Antiphospholipid antibodies in Chilean patients with systemic lupus erythematosus. J Lab Clin Med 2002; 140: 336-341 (Pubitemid 35302026)
13. LASKIN C, CLARK C, SPITZER K: Antiphospholipid syndrome in systemic lupus erythematosus: is the whole greater than the sum of its parts? Rheum Dis Clin North Am 2005; 31: 255-72, vi.
14. 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457-462
15. BEVERS E, GALLI M, BARBUI T et al.: Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-632
16. GALLI M, WILLEMS G, ROSING J et al.: Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein C. Br J Haematol 2005; 129: 240-247
17. RAND J, WU X: Antibody-mediated interference with annexins in the antiphospholipid syndrome. Thromb Res 2004; 114: 383-389
18. ADAMS M, BRECKLER L. STEVENS P et al.: Anti-tissue factor pathway inhibitor activity in subjects with antiphospholipid syndrome is associated with increased thrombin generation. Haematologica 2004; 89: 985-990
19. 2GPI) in the activation of plasminogen. Biochim Biophys Acta 2006; 1764: 815-823
20. HARRIS S, JONES D, GALLIMORE M et al.: The antigenic binding site(s) of antibodies to factor XII associated with the antiphospholipid syndrome. J Thromb Haemost 2005; 3: 969-975
21. SUGI T, MCINTYRE J: Certain autoantibodies to phosphatidylethanolamine (aPE) recognize factor XI and prekallikrein independently or in addition to the kininogens. J Autoimmun 2001; 17: 207-214
22. BIDOT C, JY W, HORSTMAN L et al.: Factor VII/VIIa: a new antigen in the anti-phospholipid antibody syndrome. Br J Haematol 2003; 120: 618-626
23. 2Glycoprotein I and antiphospholipid syndrome. Isr J Med Sci 1997; 33: 225-238
24. HULSTEIN J, LENTING P, DE LAAT B et al.: Beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood 2007; 110: 1483-91.
25. PIERANGELI S, CHEN P, GONZALEZ E: Anti-phospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. Curr Opin Hematol 2006; 13: 366-375
26. PIERANGELI SS, CHEN PP, RASCHI E et al.: Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Haemost 2008; 34: 236-250
27. MERONI PL: Pathogenesis of the antiphospholipid syndrome: an additional example of the mosaic of autoimmunity. J Autoimmun 2008; 30: 99-103.
28. 2-glycoprotein I monoclonal antibodies. Blood 2005; 106: 1629-35.
29. YANG C, HWANG K, YAN W et al.: Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J Immunol 2004; 172: 5765-5773
30. CHEN X, GU Y, LI S et al.: Some plasmin-induced antibodies bind to cardiolipin, display lupus anticoagulant activity and induce fetal loss in mice. J Immunol 2007; 178: 5351-5356
31. LU C, HORIZON A, HWANG K et al.: Identification of plyclonal and monoclonal antibodies against tissue plasminogen activador in the antiphospholipid syndrome. Arthritis Rheum 2005; 52: 4018-4027
32. 2- glycoprotein I or prothrombin. Clin Immunol 2004; 112: 150-160
33. ADAMS M, DONOHOE S, MACKIE I et al.: Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome. Br J Haematol 2001; 114: 375-379
34. YASUDA S, BOHGAKI M, ATSUMI T et al.: Pathogenesis of antiphospholipid antibodies: impairment of fibrinolysis and monocyte activation via the p38 mitogen-activated protein kinase pathway. Immunobiology 2005; 210: 775-780
35. 2-glycoprotein I, and fibrinolysis. Thromb Res 2004; 114: 461-465
36. PIERANGELI S, ESPINOLA R, LIU X et al.: Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res 2001; 88: 245-250
37. PIERANGELI S, HARRIS E: Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells. Lupus 2003; 12: 539-545
38. MERONI P, RASCHI E, CAMERA M et al.: Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. J Autoimmun 2000; 15: 237-240
39. ZHOU H, WOLBERG AS, ROUBEY AS: Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004; 15: 2353-2358 (Pubitemid 39331833)
40. CUADRADO M, BUENDIA P, VELASCO F et al.: Vascular endotelial growth factor expression in monocytes from patients with primary antiphospholipid sindrome. J Thromb Haemost 2006; 4: 2461-2469
41. VEGA-OSTERTAG M, CASPER K, SWERLICK R et al.: Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 2005; 52: 1545-1554 (Pubitemid 40663946)
42. VEGA-OSTERTAG ME, FERRARA DE, ROMAY-PENABAD Z et al.: Role of p38 mitogen-activated protein kinase in antiphopholipid-mediated thrombosis and endothelial cell activation. J Thromb Haemost 2007; 5: 1825-1827
43. 2glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001; 44: 2870-2878
44. FERRARA DE, LIU X, ESPlNOLA RG et al.: Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003; 48: 3272-3279
45. FERRARA DE, SWERLICK R, CASPER K et al.: Fluvastatin inhibitos up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost 2004; 2: 1558-1563
46. LOPEZ-PEDRERA C, BUENDIA P, CUADRADO M et al.: Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum 2006; 54: 301-311
47. AMENGUAL O, ATSUMI T, KHAMASHTA M et al.: The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79: 276-281 (Pubitemid 28065869)
48. REVERTER J, TASSIES D, FONT J et al.: Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum 1998; 41: 1420-1427
49. KORNBERG A, BLANK M, KAUFMAN S et al.: Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994; 153: 1328-1332
50. DE PROST D, OLLlVIER V, TERNISIEN C et al.: Increased monocyte procoagulant activity independent of the lupus anticoagulant in patients with systemic lupus erythematosus. Thromb Haemost 1990; 64: 216-221
51. MARTINI F, FARSI A, GORI A et al.: Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus. Lupus 1996; 5: 206-211 (Pubitemid 26197478)
52. BOHGAKI M, ATSUMI T, YAMASHITA Y et al.: The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies. Int Immunol 2004; 16: 1633-1641
53. JOSEPH J, HARRISON P, MACKIE I et al.: Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol 2001; 115: 451-459
54. CAMPBELL A, PIERANGELI S, WELLHAUSEN S et al.: Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 1995; 73: 529-534
55. BIDOT C, JY W, HORSTMAN L et al.: Antiphospholipid antibodies and platelet activation as risk factors for thrombosis in thrombocythaemia. Hematology 2005; 10: 451-456
56. ESPINOLA R, PIERANGELI S, GHARAVI A et al.: Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002; 87: 518-522
57. ROBBINS D, LEUNG S, MILLER-BLAIR D et al.: Effect of anticardiolipin/ beta2-glycoprotein I complexes on production of thromboxane A2 by platelets from patients with the antiphospholipid syndrome. J Rheumatol 1998; 25: 51-56
58. VEGA-OSTERTAG M, HARRIS E, PIERANGELI S: Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum 2004; 50: 2911-2919
59. GIRARDI G, BERMAN J, REDECHA P et al.: Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112: 1644-54.
60. PIERANGELI S, GIRARDI G, VEGA-OSTERTAG M et al.: Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum 2005; 52: 2120-2124 (Pubitemid 40994335)
61. 2glycoprotein I is complement dependent and requires a priming factor. Blood 2005; 106: 2340-2345
62. MERONI P, RASCHI E, TESTONI C et al.: Innate immunity in the antiphospholipid syndrome: role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies. Autoimmun Rev 2004; 3: 510-515
63. 2glycoprotein I antibodies. Blood 2005; 105: 1964-1969 (Pubitemid 40731779)
64. LUTTERS B, DERKSEN R, TEKELENBURG W et al.: Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2′. J Biol Chem 2003; 278: 33831-33838
65. RASCHI E, TESTONI C, BOSISIO D et al.: Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood 2003; 101: 3495-3500
66. PIERANGELI S, VEGA-OSTERTAG M, RASCHIE et al.: Toll Like Receptor 4 is involved in antiphospholipid-mediated thrombosis: In vivo studies. Ann Rheum Dis 2007; 66: 1327-1333
67. SATTA N, DUNOYER-GEINDRE S, REBER G et al.: The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood 2006; 109: 1507-1514
68. MA K, SIMANTOV R, ZHANG J et al.: High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem 2000; 275: 15541-15548
69. MERONI P, TlNCANI A, SEPP N et al.: Endothelium and the brain in CNS lupus. Lupus 2003; 12: 919-928
70. DE GROOT P, VAN LUMMEL M. PENNINGS M et al.: Beta2-glycoprotein I and LDL-receptor family members. Thromb Res 2004; 114: 455-459
71. VAN LUMMEL M, PENNINGS M, DERKSEN R et al.: The binding site in beta2-glycoprotein I for ApoER2′ on platelets is located in domain V. J Biol Chem 2005; 280: 36729-36736
72. 2glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: association with increased excretion of platelet-derived thromboxane urinary metabolites. Thromb Haemost 1998; 79: 42-45
73. MARTINUZZO M, MACLOUF J, CARRERAS L et al.: Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemost 1993; 70: 667-671
74. SHOENFELD Y: Sytemic Antiphospholipid Syndrome. Lupus 2003; 12: 497-498
75. WARE-BRANCH DW, ELLER A: Antiphospholipid syndrome and thrombosis. Clin Obstet Gynecol 2006; 49: 861-874
76. ROBERTSON B, GREAVES M: Antiphospholipid syndrome: an evolving story. Blood Rev 2006; 20: 201-212
77. BREY RL, GHARAVI AE, LOCKSHIN MD: Neurologic complication of antiphospholipid antibodies. Rheum Dis Clin North Am 1993; 19: 833-850
78. BARACZKA K, LAKOS G, SIPKA S: Immunoserological changes in the cerebro-spinal fluid and serum in systemic lupus erythematosus patients with demyelinating syndrome and multiple sclerosis. Acta Neurol Scand 2002; 105: 378-383
79. LIOU H, WANG C, CHEN C et al.: Elevated levels of anticardiolipin antibodies and epilepsy in lupus patients. Lupus 1996; 5: 307-12.
80. TIETJEN G, DAY M, NORRIS L et al.: Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events: a prospective study. Neurology 1998; 50: 1433-1440
81. SUAREZ-ALVAREZ L, HUGHES GR, KHAMASHTA MA: Neurological manifestations of the antiphospholipid syndrome. Med Clin (Barc) 2005; 124: 630-633
82. BRENNER B, BLUMENFELD Z, MARKIEWICZ W et al.: Cardiac involvement in patients with primary antiphospholipid syndrome. J Am Coll Cardiol 1991; 18: 931-936
83. CERVERA R: Coronary and valvular syndromes and antiphospholipid antibodies. Thromb Res 2004; 114: 501-507 (Pubitemid 39422584)
84. HOJNIK M, GEORGE J, ZIPOREN L, SHOENFELD Y: Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 1996; 93: 1579-1587 (Pubitemid 26115423)
85. DI SIMONE N, LUIGI M, MARCO D: Pregnancies complicated with antiphospholipid syndrome:the pathogenic mechanism of antiphospholipid antibodies: a review of the literature. Ann N Y Acad Sci 2007; 1108: 505-514
86. SALMON J, GIRARDI G: Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. J Reprod Immunol 2008; 77: 51-56
87. DAUGAS E, NOCHY D, HUONG DL et al.: Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol 2002; 13: 42-52. (Pubitemid 34042010)
88. NOCHY D, DAUGAS E, DROZ D et al.: The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol 1999; 10: 507-518 (Pubitemid 29117632)
89. MORONI G, VENTURA D, RIVA P et al.: Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 2004; 43: 28-36.
90. STOJANOVICH L: Pulmonary manifestations in antiphospholipid syndrome. Autoimmun Rev 2006; 5: 344-348
91. HSIAO Y, JOU J, LIN S et al.: Primary antiphospholipid syndrome manifested as venous stasis retinopathy. Zhonghua Yi Xue Za Zhi (Taipei) 2000; 63: 498-502.
92. KURZ R, EDER A, BUCK J, HEINKELEIN J: [Mesenteric infarct in primary antiphospholipid antibody syndrome]. Z Gastroenterol 1997; 35: 669-672
93. MIHAS A: Gastrointestinal bleeding and intestinal ischemia associated with anticardiolipin antibodies. Dig Dis Sci 1995; 40: 1039-1040
94. TINCANI A, BOZZETTI F, TARDANICO R et al.: Antiphospholipid antibodies and intestinal pathology. J Rheumatol 1993; 20: 2169-70.
95. SEKIGAWA I, IKEDA K, MATSUSHITA M et al.: Endocrine disorders and antiphospholipid antibodies. Clin Exp Rheumatol 2000; 18: 266.
96. SHARMA B, KAPOOR S, MALAVIYA A: Refractory thrombocytopenia in antiphospholipid syndrome. J Assoc Physicians India 2005; 53: 147-149
97. ASHERSON R, FRANCES C, IACCARINO L et al.: The antiphospholipid antibody syndrome: diagnosis, skin manifestations and current therapy. Clin Exp Rheumatol 2006; 24: S46-51.
98. TOUBI E, SHOENFELD Y: Livedo reticularis as a criterion for antiphospholipid syndrome. Clin Rev Allergy Immunol. 2007; 32: 138-144
99. ROVENSKY K: Asherson syndrome - catastrophic antiphospholipid syndrome. Autoimmun Rev 2006; 6: 61-63
100. ESPINOSA G, BUCCIARELLI S, CERVERA R et al.: Laboratory studies on pathophysiology of the catastrophic antiphospholipid syndrome. Autoimmun Rev 2006; 6: 68-71.
101. BUCCIARELLI S, CERVERA R, ESPINOSA G et al.: Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors. Autoimmun Rev 2006; 6: 72-75 (Pubitemid 44810177)
102. ERKAN D: Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome. Autoimmun Rev 2006; 6: 98-103. (Pubitemid 44816525)
103. ASHERSON RA: New subsets of the antiphospholipid syndrome in 2006: "PREAPS" (probable APS) and microangiopathic antiphospholipid syndrome ("MAPS"). Auto-immun Rev 2006; 6: 76-80.
104. WILSON W, GHARAVI A, KOIKE T et al.: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311
105. MiYAKIS S, LOCKSHIN M, ATSUMI T et al.: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
106. HNAZZI G, MARCHIOLI R, BRANCACCIO V et al.: A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848-853
107. KHAMASHTA M, CUADRADO M, MUJIC F et al.: The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-997
108. KRNIC-BARRIE S, O'CONNOR C, LOONEY S et al.: A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch Intern Med 1997; 157: 2101-2108
109. CROWTHER M, GINSBERG J, JULIAN J et al.: A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-1138
110. LOCKSHIN M: Update on antiphospholipid syndrome. Bull NYU Hosp Jt Dis 2006; 64: 57-59
111. ERKAN D, LOCKSHIM M: Antiphospholipid syndrome. Curr Opin Rheumatol 2006; 18: 242-248
112. ASHERSON R: Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson's) syndrome. Immunobiology 2005; 210: 727-733
113. RUBENSTEIN E, ARKFELD D, METYAS S et al.: Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 2006; 33: 355-357 (Pubitemid 43209314)
114. AHN E, LANDER G, BIDOT C et al.: Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapy. Am J Hematol 2005; 78: 127-129
115. TOMIETTO P, GREMESE E, TOLUSSO B et al.: B cell depletion may lead to normalization of anti-platelet, anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus. Thromb Haemost 2004; 92: 1150-1153
116. RAI R, COHEN H, DAVE M et al.: Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). British Med J 1997; 314: 253-257
117. EDWARDS M, PIERANGELI S, LIU X et al.: Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997; 96: 4380-4384